Lista de obras - Nathalie Chaput - Dominio Público Uruguay

A novel dendritic cell subset involved in tumor immunosurveillance

artículo científico publicado en 2006

Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors

artículo científico publicado en 2011

An inhibitor of cyclin-dependent kinases suppresses TLR signaling and increases the susceptibility of cancer patients to herpesviridae.

artículo científico publicado en 2011

Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota

artículo científico publicado en 2015

Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25.

artículo científico publicado en 2015

Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab

artículo científico publicado en 2017

CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner

artículo científico publicado en 2005

Calreticulin exposure on malignant blasts predicts a cellular anticancer immune response in patients with acute myeloid leukemia

artículo científico publicado en 2010

Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease

scientific article published on 18 January 2016

Cancer-Induced Immunosuppression: IL-18-Elicited Immunoablative NK Cells

artículo científico publicado en 2012

Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death

artículo científico publicado en 2005

Clinical impact of the NKp30/B7-H6 axis in high-risk neuroblastoma patients

artículo científico publicado en 2015

Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy

artículo científico publicado en 2011

Contribution of IL-17–producing γδ T cells to the efficacy of anticancer chemotherapy

Ctla-4 blockade confers lymphocyte resistance to regulatory T-cells in advanced melanoma: surrogate marker of efficacy of tremelimumab?

artículo científico publicado en 2008

Dendritic cell derived-exosomes: biology and clinical implementations

artículo científico publicado en 2006

Dendritic cell maturation overrules H-2D-mediated natural killer T (NKT) cell inhibition: critical role for B7 in CD1d-dependent NKT cell interferon gamma production

artículo científico publicado en 2001

Dendritic cell-derived exosomes as cell-free peptide-based vaccines

artículo científico publicado en 2005

Dendritic cell-derived exosomes as immunotherapies in the fight against cancer

artículo científico publicado en 2014

Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC.

artículo científico publicado en 2015

Dendritic cell-derived exosomes for cancer immunotherapy: what's next?

artículo científico publicado en 2010

Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15Ralpha

artículo científico publicado en 2009

Dendritic cells and innate defense against tumor cells

artículo científico publicado en 2007

Ecto-calreticulin in immunogenic chemotherapy

artículo científico publicado en 2007

Erratum: anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25.

artículo científico publicado en 2015

Exosome-based immunotherapy

artículo científico publicado en 2004

Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells

artículo científico publicado en 2004

Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejection

artículo científico

Exosomes for immunotherapy of cancer.

artículo científico publicado en 2003

Exosomes for the treatment of human malignancies

artículo científico publicado en 2008

Exosomes: immune properties and potential clinical implementations

artículo científico publicado en 2010

From the antigen-presenting cell to the antigen-presenting vesicle: the exosomes.

artículo científico publicado en 2002

Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine

artículo científico

Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1.

artículo científico publicado en 2016

IL-15 Trans-Signaling with the Superagonist RLI Promotes Effector/Memory CD8+ T Cell Responses and Enhances Antitumor Activity of PD-1 Antagonists.

artículo científico publicado en 2016

IL-21-Induced MHC Class II+ NK Cells Promote the Expansion of Human Uncommitted CD4+ Central Memory T Cells in a Macrophage Migration Inhibitory Factor-Dependent Manner.

artículo científico publicado en 2016

IL-4 confers NK stimulatory capacity to murine dendritic cells: a signaling pathway involving KARAP/DAP12-triggering receptor expressed on myeloid cell 2 molecules

artículo científico publicado en 2004

Imatinib mesylate (Gleevec): targeted therapy against cancer with immune properties

scientific article published on March 2010

Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors

artículo científico publicado en 2013

Immune response against dying tumor cells

artículo científico publicado en 2004

Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway

artículo científico publicado en 2010

Immunomodulatory effects of cyclophosphamide and implementations for vaccine design

artículo científico publicado en 2011

Inflammatory bowel disease and cancer response due to anti-CTLA-4: is it in the flora?

artículo científico publicado en 2017

Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies

artículo científico publicado en 2017

Integrating Circulating Biomarkers in the Immune Checkpoint Inhibitor Treatment in Lung Cancer

artículo científico publicado en 2020

Interferon-gamma is produced by another player of innate immune responses: the interferon-producing killer dendritic cell (IKDC).

artículo científico publicado en 2007

Killer dendritic cells and their potential role in immunotherapy

artículo científico publicado en 2008

Killer dendritic cells: IKDC and the others

artículo científico publicado en 2008

Molecular determinants of immunogenic cell death: surface exposure of calreticulin makes the difference

artículo científico publicado en 2007

Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients

artículo científico publicado en 2009

Natural killer cell-directed therapies: moving from unexpected results to successful strategies

scientific article published on May 2008

Natural killer cells in non-hematopoietic malignancies

artículo científico publicado en 2012

Opposing effects of toll-like receptor (TLR3) signaling in tumors can be therapeutically uncoupled to optimize the anticancer efficacy of TLR3 ligands

artículo científico publicado en 2010

Phase I clinical trial combining imatinib mesylate and IL-2 in refractory cancer patients: IL-2 interferes with the pharmacokinetics of imatinib mesylate

artículo científico publicado en 2013

Phase I clinical trial combining imatinib mesylate and IL-2: HLA-DR(+) NK cell levels correlate with disease outcome

artículo científico publicado en 2013

Potent immunomodulatory effects of the trifunctional antibody catumaxomab

artículo científico publicado en 2013

Predictive biomarkers for programmed death-1/programmed death ligand immune checkpoint inhibitors in nonsmall cell lung cancer

artículo científico publicado en 2016

Prognostic value of HLA-A2 status in advanced non-small cell lung cancer patients

artículo científico publicado en 2017

Regulation of CD4(+)NKG2D(+) Th1 cells in patients with metastatic melanoma treated with sorafenib: role of IL-15Rα and NKG2D triggering

artículo científico publicado en 2013

Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer

artículo científico publicado en 2020

The Janus face of dendritic cells in cancer

artículo científico publicado en 2008

The critical role of IL-15 in the antitumor effects mediated by the combination therapy imatinib and IL-2.

artículo científico publicado en 2008

The dendritic cell-like functions of IFN-producing killer dendritic cells reside in the CD11b+ subset and are licensed by tumor cells

artículo científico publicado en 2009

The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy

artículo científico publicado en 2007

The potential of exosomes in immunotherapy

artículo científico publicado en 2005

The potential of exosomes in immunotherapy of cancer

artículo científico publicado en 2005

Therapy-induced tumor immunosurveillance involves IFN-producing killer dendritic cells

artículo científico publicado en 2007

Trans-presentation of IL-15 dictates IFN-producing killer dendritic cells effector functions

artículo científico publicado en 2008

Treatment of gastric peritoneal carcinomatosis by combining complete surgical resection of lesions and intraperitoneal immunotherapy using catumaxomab

artículo científico publicado en 2014

Tumour-infiltrating CD68+ and CD57+ cells predict patient outcome in stage II-III colorectal cancer

artículo científico publicado en 2013

Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial

artículo científico publicado en 2005

Lista de obras de Nathalie Chaput

A novel dendritic cell subset involved in tumor immunosurveillance

Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors

An inhibitor of cyclin-dependent kinases suppresses TLR signaling and increases the susceptibility of cancer patients to herpesviridae.

Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota

Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25.

Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab

CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner

Calreticulin exposure on malignant blasts predicts a cellular anticancer immune response in patients with acute myeloid leukemia

Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease

Cancer-Induced Immunosuppression: IL-18-Elicited Immunoablative NK Cells

Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death

Clinical impact of the NKp30/B7-H6 axis in high-risk neuroblastoma patients

Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy

Contribution of IL-17–producing γδ T cells to the efficacy of anticancer chemotherapy

Ctla-4 blockade confers lymphocyte resistance to regulatory T-cells in advanced melanoma: surrogate marker of efficacy of tremelimumab?

Dendritic cell derived-exosomes: biology and clinical implementations

Dendritic cell maturation overrules H-2D-mediated natural killer T (NKT) cell inhibition: critical role for B7 in CD1d-dependent NKT cell interferon gamma production

Dendritic cell-derived exosomes as cell-free peptide-based vaccines

Dendritic cell-derived exosomes as immunotherapies in the fight against cancer

Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC.

Dendritic cell-derived exosomes for cancer immunotherapy: what's next?

Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15Ralpha

Dendritic cells and innate defense against tumor cells

Ecto-calreticulin in immunogenic chemotherapy

Erratum: anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25.

Exosome-based immunotherapy

Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells

Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejection

Exosomes for immunotherapy of cancer.

Exosomes for the treatment of human malignancies

Exosomes: immune properties and potential clinical implementations

From the antigen-presenting cell to the antigen-presenting vesicle: the exosomes.

Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine

Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1.

IL-15 Trans-Signaling with the Superagonist RLI Promotes Effector/Memory CD8+ T Cell Responses and Enhances Antitumor Activity of PD-1 Antagonists.

IL-21-Induced MHC Class II+ NK Cells Promote the Expansion of Human Uncommitted CD4+ Central Memory T Cells in a Macrophage Migration Inhibitory Factor-Dependent Manner.

IL-4 confers NK stimulatory capacity to murine dendritic cells: a signaling pathway involving KARAP/DAP12-triggering receptor expressed on myeloid cell 2 molecules

Imatinib mesylate (Gleevec): targeted therapy against cancer with immune properties

Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors

Immune response against dying tumor cells

Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway

Immunomodulatory effects of cyclophosphamide and implementations for vaccine design

Inflammatory bowel disease and cancer response due to anti-CTLA-4: is it in the flora?

Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies

Integrating Circulating Biomarkers in the Immune Checkpoint Inhibitor Treatment in Lung Cancer

Interferon-gamma is produced by another player of innate immune responses: the interferon-producing killer dendritic cell (IKDC).

Killer dendritic cells and their potential role in immunotherapy

Killer dendritic cells: IKDC and the others

Molecular determinants of immunogenic cell death: surface exposure of calreticulin makes the difference

Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients

Natural killer cell-directed therapies: moving from unexpected results to successful strategies

Natural killer cells in non-hematopoietic malignancies

Opposing effects of toll-like receptor (TLR3) signaling in tumors can be therapeutically uncoupled to optimize the anticancer efficacy of TLR3 ligands

Phase I clinical trial combining imatinib mesylate and IL-2 in refractory cancer patients: IL-2 interferes with the pharmacokinetics of imatinib mesylate

Phase I clinical trial combining imatinib mesylate and IL-2: HLA-DR(+) NK cell levels correlate with disease outcome

Potent immunomodulatory effects of the trifunctional antibody catumaxomab

Predictive biomarkers for programmed death-1/programmed death ligand immune checkpoint inhibitors in nonsmall cell lung cancer

Prognostic value of HLA-A2 status in advanced non-small cell lung cancer patients

Regulation of CD4(+)NKG2D(+) Th1 cells in patients with metastatic melanoma treated with sorafenib: role of IL-15Rα and NKG2D triggering

Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer

The Janus face of dendritic cells in cancer

The critical role of IL-15 in the antitumor effects mediated by the combination therapy imatinib and IL-2.

The dendritic cell-like functions of IFN-producing killer dendritic cells reside in the CD11b+ subset and are licensed by tumor cells

The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy

The potential of exosomes in immunotherapy

The potential of exosomes in immunotherapy of cancer

Therapy-induced tumor immunosurveillance involves IFN-producing killer dendritic cells

Trans-presentation of IL-15 dictates IFN-producing killer dendritic cells effector functions

Treatment of gastric peritoneal carcinomatosis by combining complete surgical resection of lesions and intraperitoneal immunotherapy using catumaxomab

Tumour-infiltrating CD68+ and CD57+ cells predict patient outcome in stage II-III colorectal cancer

Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial